Arvinas Stock Price - ARVN

0.00 (0.00%)
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Arvinas Inc ARVN NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.25 -0.53% 47.13 44.5577 47.25 45.73 47.38 16:30:00
Bid Price Ask Price Spread Spread % News
45.00 47.25 2.25 4.76% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
3,636 285,507 $ 45.65 $ 13,033,739 296,384 14.065 - 54.95
Last Trade Time Type Quantity Stock Price Currency
16:37:40 8 $ 47.13 USD

Arvinas Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 1.84B 38.98M $ -41.48M -26.77 - 37.65M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 1.00 3.40%

more financials information »

Arvinas News

Loading Messages....

Latest ARVN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ARVN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week50.5851.472444.557748.84326,633-3.45-6.82%
1 Month49.8454.9544.557750.56319,422-2.71-5.44%
3 Months38.0054.9537.8546.14325,0479.1324.03%
6 Months23.8754.9515.18534.90325,31123.2697.44%
1 Year19.7254.9514.06530.36246,52727.41139.0%
3 Years21.0054.9510.1927.79215,29826.13124.43%
5 Years21.0054.9510.1927.79215,29826.13124.43%

Arvinas Description

Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.